ICER seeks input on assessment for serious ultra-rare conditions

ICER seeks input on assessment for serious ultra-rare conditions PharmacoEconomics & Outcomes News 784, p5 - 12 Aug 2017 ICER seeks input on assessment for serious ultra-rare conditions The Institute for Clinical and Economic Review (ICER) is seeking public comment on proposed changes to its value assessment framework for treatments for serious ultra-rare conditions. Although the ICER’s fundamental approach to value assessment is unchanged, these adaptations reflect the particular ethical and practical considerations associated with treatments that could potentially offer major advances for ultra-rare conditions. Treatments will qualify if they offer a significant gain in quality or length of life for serious conditions that affect a population of less than 10 000 patients, with little chance of future increases in patient population or indication. Discussion on the need to distinguish ways to assess treatment for rare conditions was prompted by an ICER white paper, followed by an all-stakeholder meeting held in May 2017 in Washington, DC, during which the proposed adaptations were developed. The changes include consideration of the potential challenges of generating evidence for treatments for ultra-rare conditions, as well as inclusion of a broader range of cost-effectiveness thresholds, from $US50 000 to $500 000 per quality-adjusted life-year. The adaptations will also include wider consideration of the effects of new treatments on family, school and community, as well as the impact on infrastructure for patient screening and care. The ICER aims to collaboratively design a template for the provision of information on research, development and other costs relevant to new treatments for serious ultra-rare conditions. In the meantime, the ICER will work with individual treatment manufacturers to decide what cost information is shared for public deliberation. The proposed adaptations are open for public comment until Monday, 25 September 2017. Institute for Clinical and Economic Review. ICER Seeks Public Comment on Proposed Value Assessment Framework for Treatments That Represent a Potential Major Advance for Serious Ultra-Rare Conditions. Internet Document : 25 Jul 2017. Available from: URL: https://icer-review.org/announcements/proposed-vaf- changes-ultra-rare/ 803263659 1173-5503/17/0784-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 12 Aug 2017 No. 784 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png PharmacoEconomics & Outcomes News Springer Journals

ICER seeks input on assessment for serious ultra-rare conditions

Free
1 page

Loading next page...
1 Page
 
/lp/springer_journal/icer-seeks-input-on-assessment-for-serious-ultra-rare-conditions-FbQP6uxOAS
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Springer International Publishing AG
Subject
Medicine & Public Health; Pharmacoeconomics and Health Outcomes; Quality of Life Research; Health Economics; Public Health
ISSN
1173-5503
eISSN
1179-2043
D.O.I.
10.1007/s40274-017-4216-0
Publisher site
See Article on Publisher Site

Abstract

PharmacoEconomics & Outcomes News 784, p5 - 12 Aug 2017 ICER seeks input on assessment for serious ultra-rare conditions The Institute for Clinical and Economic Review (ICER) is seeking public comment on proposed changes to its value assessment framework for treatments for serious ultra-rare conditions. Although the ICER’s fundamental approach to value assessment is unchanged, these adaptations reflect the particular ethical and practical considerations associated with treatments that could potentially offer major advances for ultra-rare conditions. Treatments will qualify if they offer a significant gain in quality or length of life for serious conditions that affect a population of less than 10 000 patients, with little chance of future increases in patient population or indication. Discussion on the need to distinguish ways to assess treatment for rare conditions was prompted by an ICER white paper, followed by an all-stakeholder meeting held in May 2017 in Washington, DC, during which the proposed adaptations were developed. The changes include consideration of the potential challenges of generating evidence for treatments for ultra-rare conditions, as well as inclusion of a broader range of cost-effectiveness thresholds, from $US50 000 to $500 000 per quality-adjusted life-year. The adaptations will also include wider consideration of the effects of new treatments on family, school and community, as well as the impact on infrastructure for patient screening and care. The ICER aims to collaboratively design a template for the provision of information on research, development and other costs relevant to new treatments for serious ultra-rare conditions. In the meantime, the ICER will work with individual treatment manufacturers to decide what cost information is shared for public deliberation. The proposed adaptations are open for public comment until Monday, 25 September 2017. Institute for Clinical and Economic Review. ICER Seeks Public Comment on Proposed Value Assessment Framework for Treatments That Represent a Potential Major Advance for Serious Ultra-Rare Conditions. Internet Document : 25 Jul 2017. Available from: URL: https://icer-review.org/announcements/proposed-vaf- changes-ultra-rare/ 803263659 1173-5503/17/0784-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 12 Aug 2017 No. 784

Journal

PharmacoEconomics & Outcomes NewsSpringer Journals

Published: Aug 12, 2017

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off